Full Text of PDF (612k)
Article in Japanese
Abstract
Topics Series Allergy, immunology and inflammation
Molecular-targeting drugs
National Hospital Organization Tokyo National Hospital
ABSTRACT
A humanized anti-human IgE antibody (anti-IgE: omalizumab) was first approved for clinical use as a molecular targeting drug for asthma treatment. It has been used as a new treatment for patients with severe allergic asthma and found to be effective in about 60% of the patients. One of the developing agents following anti-IgE is a humanized anti-IL-5 antibody (mepolizumab), which showed efficacy in severe asthmatics with eosinophilia in the airways. Moreover, recombinant antibodies targeting the receptor, IL-4Ra, shared by IL-4 and IL-13 or IL-13 itself, and a humanized antibody against the IL-5 receptor have been under investigation.
KEYWORDS
Humanized anti-human IgE antibody JGL2012 Refractory asthma Humanized anti-IL-5 antibody Humanized anti-IL-13 antibody
AJRS, 3(2): 178-185, 2014
Copyright © The Japanese Respiratory Society All Rights Reserved.